BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Docket Clock//docket-clock.pages.dev//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Financial Transparency and Efficiency of the Prescription Dr
X-PUBLISHED-TTL:PT12H
REFRESH-INTERVAL;VALUE=DURATION:PT12H
BEGIN:VEVENT
UID:2026-07248-close@docket-clock.pages.dev
DTSTAMP:20261017T145145Z
DTSTART;VALUE=DATE:20260723
DTEND;VALUE=DATE:20260724
SUMMARY:FDA comments close: Financial Transparency and Efficiency of the P
 rescription Drug User Fee Act\, Biosimilar User Fee Act\, and Generic Dru
 g User Fee Amendments\; Public Meeting\; Request for Comments
DESCRIPTION:Notice. Federal Register 2026-07248. Docket FDA-2026-N-3273. D
 etails: https://docket-clock.pages.dev/doc/2026-07248/ Official: https://
 www.federalregister.gov/documents/2026/04/15/2026-07248/financial-transpa
 rency-and-efficiency-of-the-prescription-drug-user-fee-act-biosimilar-use
 r-fee-act
URL:https://www.federalregister.gov/documents/2026/04/15/2026-07248/financ
 ial-transparency-and-efficiency-of-the-prescription-drug-user-fee-act-bio
 similar-user-fee-act
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR